Malignant peritoneal mesotheliomaNews & Research

8 curated articles for Malignant peritoneal mesothelioma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.

ℹ
UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data
  1. Digestive surgery May 12, 2026

    PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions.

    Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), but ...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  2. British journal of cancer Apr 14, 2026

    Genomic sequencing of multicystic mesothelioma finds cohesin complex mutations associated with disease recurrence in patients referred for cytoreductive surgery and HIPEC.

    Multicystic mesothelioma (MCM) is a rare disease and there is debate about it's neoplastic nature with a spectrum of disease behaviour and little known about the genomic profile. In contrast, the genomic profile of malignant peritoneal mesothelioma (MPeM) is characterised. We characterized 24 MCM an...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Apr 1, 2026

    Ascorbic Acid Analog 6-Deoxy-6- 18 F-Fluoro-l-Ascorbic Acid PET Imaging of 23 Various Cancer Types.

    High-dose ascorbic acid (AA) has shown promise as an adjunctive treatment for various cancers because of its prooxidant cytotoxicity at high concentrations and its multitargeting effects. However, identifying patients who may benefit from AA treatment remains an unmet need, as the therapeutic effica...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  4. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology Mar 29, 2026

    Ten-year of French multicentric experience in the management of peritoneal mesothelioma with 924 patients.

    Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease for which only selected patients are eligible for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of our study was to evaluate oncologic outcomes of different treatments patterns of DMPM at...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  5. Japanese journal of radiology Mar 21, 2026

    Pretreatment volume-based 18 F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients.

    This study was conducted to examine relationships of pretreatment volume-based quantitative 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients. Data for 71 patients w...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  6. Genes, chromosomes & cancer Feb 19, 2026

    Novel EWSR1::TEAD3 Fusion in an Adolescent With a Highly Aggressive Peritoneal Mesothelioma.

    Malignant peritoneal mesothelioma (MPM) is an exceptionally rare entity in children and adolescents, exhibiting distinct clinicopathological features compared to its adult counterpart. Unlike adult cases, it typically occurs without a history of asbestos exposure or BAP1 inactivation. Although sever...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  7. Frontiers in oncology Feb 19, 2026

    Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.

    To investigate the efficacy and safety of pemetrexed/platinum-based chemotherapy combined with or without bevacizumab after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of patients with malignant peritoneal mesothelioma (MPM). A retrospective no...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

  8. The American journal of case reports Feb 2, 2026

    Neoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases.

    BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The standard of care for PM is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Because of its insidious manifestations, PM is often diagnosed at...

    Why it matters: Recent peer-reviewed research on Malignant peritoneal mesothelioma that may be relevant for patients and caregivers.

More on Malignant peritoneal mesothelioma

Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.